New, Potential First-in-Class Schizophrenia Medicine Reduced Positive and Negative Symptoms in Phase 3 Trial
A new medicine for treating schizophrenia—one that appears to help reduce both positive and negative symptoms of the illness—has passed a first hurdle in phase 3 clinical testing. Phase 3 is often… Read More
A Connectivity Signature Predicting Response to Antipsychotic Therapy is Identified in First-Episode Psychosis Patients
In people who experience a first psychotic episode—often the prelude to schizophrenia and related disorders—the individual’s response to antipsychotic medicines can be crucial, and typically, varies… Read More
In Schizophrenia, Reducing the Impact of Medications on One Neurotransmitter System Could Yield Gains in Cognition
Several important insights have recently combined to provide “a new lens” on improving how people with schizophrenia are cared for. This new perspective is arguably important not only for all… Read More
Stressful Life Events Can Cause Psychosis Relapse, Study Finds
There is considerable evidence that exposure to stressful life events can increase the risk that a vulnerable individual will go on to have a first psychotic episode. It has also been established… Read More
Lumateperone, an Antipsychotic, is Tested in a Phase 3 Trial for Major Depressive Episodes in Bipolar I and II Disorders
An international team of researchers has reported positive results in a phase 3 clinical trial of a drug to treat depressive episodes in patients with bipolar I and bipolar II disorder. Read More